Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
BMC Cancer. 2022 Mar 25;22(1):326. doi: 10.1186/s12885-022-09401-x.
This study aimed to compare the survival outcomes between squamous cell carcinoma (SCC) and adenocarcinoma/adenosquamous carcinoma (AC/ASC) of the cervix after radical radiotherapy and chemotherapy.
Propensity score matching (1:4) was used to compare overall survival (OS) and disease-free survival (DFS) in cervical cancer patients with SCC and AC/ASC in China.
Five thousand four hundred sixty-six patients were enrolled according to the criteria. The 5-year OS and DFS in the SCC group (n = 5251) were higher than those in the AC/ASC group (n = 215). After PSM (1:4), the 5-year OS and DFS in the SCC group were higher than those in the AC/ASC group (72.2% vs 56.9%, p < 0.001, HR = 1.895; 67.6% vs 47.8%, p < 0.001, HR = 2.056). In stage I-IIA2 patients, after PSM (1:4), there was no significant difference in 5-year OS between the SCC group (n = 143) and the AC/ASC group (n = 34) (68.5% vs 67.8%, P = 0.175). However, the 5-year DFS in the SCC group was higher than that in the AC/ASC group (71.0% vs 55.7%, P = 0.045; HR = 2.037, P = 0.033). In stage IIB-IV patients, after PSM (1:4), the 5-year OS and DFS in the SCC group (n = 690) were higher than those in the AC/ASC group (n = 173) (70.7% vs 54.3% P < 0.001 vs 1.940%, P < 0.001 vs 45.8%, p < 0.001).
For stage I-IIA2, there was no significant difference in 5-year survival time, but patients with AC/ASC were more likely to relapse. In the more advanced IIB-IV stage, the oncological outcome of radical radiotherapy and chemotherapy of cervical AC/ASC was worse than that of SCC.
本研究旨在比较根治性放化疗后宫颈鳞癌(SCC)和腺癌/腺鳞癌(AC/ASC)患者的生存结局。
采用倾向评分匹配(1:4)比较中国 SCC 和 AC/ASC 宫颈癌患者的总生存(OS)和无病生存(DFS)。
根据标准纳入了 5466 名患者。SCC 组(n=5251)的 5 年 OS 和 DFS 高于 AC/ASC 组(n=215)。PSM(1:4)后,SCC 组的 5 年 OS 和 DFS 高于 AC/ASC 组(72.2%比 56.9%,p<0.001,HR=1.895;67.6%比 47.8%,p<0.001,HR=2.056)。在Ⅰ-IIA2 期患者中,PSM(1:4)后 SCC 组(n=143)和 AC/ASC 组(n=34)的 5 年 OS 无显著差异(68.5%比 67.8%,P=0.175)。然而,SCC 组的 5 年 DFS 高于 AC/ASC 组(71.0%比 55.7%,P=0.045;HR=2.037,P=0.033)。在ⅡB-IV 期患者中,PSM(1:4)后 SCC 组(n=690)的 5 年 OS 和 DFS 高于 AC/ASC 组(n=173)(70.7%比 54.3%,P<0.001;HR=1.940,P<0.001;45.8%,P<0.001)。
对于Ⅰ-IIA2 期,5 年生存时间无显著差异,但 AC/ASC 患者更易复发。在更晚期的ⅡB-IV 期,根治性放化疗的宫颈 AC/ASC 患者的肿瘤学结局比 SCC 差。